Downes Kevin J, Fitzgerald Julie C, Weiss Scott L
Department of Pediatrics, The University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA
Division of Infectious Diseases, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
J Clin Microbiol. 2020 Jun 24;58(7). doi: 10.1128/JCM.01851-19.
Sepsis is a complex process defined as life-threatening organ dysfunction caused by a dysregulated host response to infection. It is associated with significant morbidity and mortality rates in both adults and children, and emphasis has been placed on its early recognition and prompt provision of antimicrobials. Owing to limitations of current diagnostic tests (i.e., poor sensitivity and delayed results), significant research has been conducted to identify sepsis biomarkers. Ideally, a biomarker could reliably and rapidly distinguish bacterial infection from other, noninfectious causes of systemic inflammatory illness. In doing so, a sepsis biomarker could be used for earlier identification of sepsis, risk stratification/prognostication, and/or guidance of antibiotic decision-making. In this minireview, we review one of the most common clinically used sepsis biomarkers, procalcitonin, and its roles in sepsis management in these three areas. We highlight key findings in the adult literature but focus the bulk of this review on pediatric sepsis. The challenges and limitations of procalcitonin measurement in sepsis are also discussed.
脓毒症是一个复杂的过程,被定义为由宿主对感染的失调反应引起的危及生命的器官功能障碍。它在成人和儿童中均与显著的发病率和死亡率相关,并且重点在于早期识别和及时给予抗菌药物。由于当前诊断测试的局限性(即敏感性差和结果延迟),已经开展了大量研究以识别脓毒症生物标志物。理想情况下,一种生物标志物能够可靠且快速地将细菌感染与其他全身性炎症疾病的非感染性病因区分开来。这样一来,一种脓毒症生物标志物可用于脓毒症的早期识别、风险分层/预后评估和/或抗生素决策指导。在本综述中,我们回顾了临床上最常用的脓毒症生物标志物之一——降钙素原,及其在脓毒症管理这三个领域中的作用。我们强调成人文献中的关键发现,但本综述的重点是儿童脓毒症。还讨论了脓毒症中降钙素原测量的挑战和局限性。